Lamassu BioTech

Lamassu BioTech Accelerating treatment, means saving more lives.

Be sure to catch Lamassu BioTech CEO Dr. Gabi Hanna's panel discussion on the integration of biotechnology and digital p...
04/24/2026

Be sure to catch Lamassu BioTech CEO Dr. Gabi Hanna's panel discussion on the integration of biotechnology and digital platforms to create smarter, more personalized therapies and diagnostics during C3 Summit International's US Sunnyvale Davos of Healthcare Summit on Monday, April 27. Interested in connecting with Dr. Hanna during the summit? Email [email protected].

With more than three decades of experience working in the field of medical oncology and radiation oncology, the 24th Com...
04/23/2026

With more than three decades of experience working in the field of medical oncology and radiation oncology, the 24th Commissioner of Food and Drugs, Dr. Stephen Hahn, has established himself as a national leader in healthcare and a distinguished physician. As the newest member of Lamassu Biotechโ€™s Board of Directors, his expertise will assist our team of physician-scientists as we advance our genetically targeted therapy, SA53, which could be transformative in treating upwards of 50% of all cancer cases including those that currently lack effective treatments.

Full announcement ๐Ÿ”— in the comments.

A clinician, national public health leader and pharmaceutical executive, Dr. Stephen Hahn brings decades of expertise to...
04/21/2026

A clinician, national public health leader and pharmaceutical executive, Dr. Stephen Hahn brings decades of expertise to Lamassu Biotech. We are excited to have him as a member of our board of directors and as an strategic advisor to Lamassu as we continue to advance SA53, and our suite of innovative therapies, through the rigorous drug development process.

Full announcement ๐Ÿ”— in the comments.

Crain's Cleveland Business : ๐…๐จ๐ซ๐ฆ๐ž๐ซ ๐…๐ƒ๐€ ๐ฅ๐ž๐š๐๐ž๐ซ ๐š๐ฉ๐ฉ๐จ๐ข๐ง๐ญ๐ž๐ ๐ญ๐จ ๐‹๐š๐ฆ๐š๐ฌ๐ฌ๐ฎ ๐๐ข๐จ๐ญ๐ž๐œ๐ก ๐›๐จ๐š๐ซ๐ ๐จ๐Ÿ ๐๐ข๐ซ๐ž๐œ๐ญ๐จ๐ซ๐ฌโ€œLamassuโ€™s team has demon...
04/17/2026

Crain's Cleveland Business : ๐…๐จ๐ซ๐ฆ๐ž๐ซ ๐…๐ƒ๐€ ๐ฅ๐ž๐š๐๐ž๐ซ ๐š๐ฉ๐ฉ๐จ๐ข๐ง๐ญ๐ž๐ ๐ญ๐จ ๐‹๐š๐ฆ๐š๐ฌ๐ฌ๐ฎ ๐๐ข๐จ๐ญ๐ž๐œ๐ก ๐›๐จ๐š๐ซ๐ ๐จ๐Ÿ ๐๐ข๐ซ๐ž๐œ๐ญ๐จ๐ซ๐ฌ

โ€œLamassuโ€™s team has demonstrated significant growth potential and a strong commitment to a rigorous scientific process,โ€ Hahn said in an emailed statement to Crainโ€™s. โ€œIt is always a pleasure to work with people who share your values and your commitment to bringing transformative medicine from the lab to the bedside.โ€

๐Ÿ”— in the comments.

Lamassu Biotech is pleased to welcome Stephen M. Hahn, MD, as our newest board member and strategic advisor. Dr. Hahn is...
04/14/2026

Lamassu Biotech is pleased to welcome Stephen M. Hahn, MD, as our newest board member and strategic advisor. Dr. Hahn is a nationally recognized leader in healthcare who served as the 24th Commissioner of Food and Drugs. He is the CEO of Nucleus RadioPharma, and former Chief Medical Executive at UT MD Anderson Cancer Center.

Dr. Hahnโ€™s expertise will help advance Lamassuโ€™s drug development process. His deep knowledge of medical and radiation oncology will assist Lamassu as we advance our genetically targeted therapy, SA53, which could be transformative in treating up to 50 percent of all cancers.

Full announcement ๐Ÿ”— in the comments.

Congratulations to our co-founder Dr. Rabi Hanna, chairman of Pediatric Oncology at Cleveland Clinic, who has published ...
04/03/2026

Congratulations to our co-founder Dr. Rabi Hanna, chairman of Pediatric Oncology at Cleveland Clinic, who has published two articles in The New England Journal of Medicine. Dr. Hanna is an internationally recognized clinical researcher in the field of transplant and gene therapy. His mission, like ours, is to always find new and better therapies to save and improve the lives of patients with life threatening disorders through innovation and bring new treatment.

๐Ÿงฌ ๐‚๐‘๐ˆ๐’๐๐‘-๐‚๐š๐ฌ๐Ÿ๐Ÿ๐š ๐†๐ž๐ง๐ž ๐„๐๐ข๐ญ๐ข๐ง๐  ๐จ๐Ÿ ๐‡๐๐†๐Ÿ ๐š๐ง๐ ๐‡๐๐†๐Ÿ ๐๐ซ๐จ๐ฆ๐จ๐ญ๐ž๐ซ๐ฌ ๐ญ๐จ ๐“๐ซ๐ž๐š๐ญ ๐’๐ข๐œ๐ค๐ฅ๐ž ๐‚๐ž๐ฅ๐ฅ ๐ƒ๐ข๐ฌ๐ž๐š๐ฌ๐ž
Dr. Hanna is the lead author in this multi-center first-in-human gene editing therapy using CRISPR/Cas12 to treat patients with severe sickle cell disease. Treatment with reni-cel led to normalization of the total hemoglobin level and an increase in the percentage of fetal hemoglobin, with no vaso-occlusive events occurring in 27 of 28 patients after infusion.
๐Ÿ”— https://www.nejm.org/doi/full/10.1056/NEJMoa2415550

๐Ÿฉธ ๐‚๐‘๐ˆ๐’๐๐‘-๐‚๐š๐ฌ๐Ÿ๐Ÿ๐š ๐†๐ž๐ง๐ž ๐„๐๐ข๐ญ๐ข๐ง๐  ๐จ๐Ÿ ๐‡๐๐†๐Ÿ ๐š๐ง๐ ๐‡๐๐†๐Ÿ ๐๐ซ๐จ๐ฆ๐จ๐ญ๐ž๐ซ๐ฌ ๐ญ๐จ ๐“๐ซ๐ž๐š๐ญ ฮฒ-๐“๐ก๐š๐ฅ๐š๐ฌ๐ฌ๐ž๐ฆ๐ข๐š
Dr. Hanna was the second author on a paper that reviewed a phase 1โ€“2, multicenter, open-label, single-group study of reni-cel in participants 18 to 35 years of age with transfusion-dependent ฮฒ-thalassemia. The participants received myeloablative conditioning with busulfan before reni-cel infusion.
Nine participants with transfusion-dependent ฮฒ-thalassemia (four ฮฒ0/ฮฒ0 or ฮฒ0/ฮฒ0-like and five nonโ€“ฮฒ0/ฮฒ0 genotypes) received reni-cel and were included in the analysis...All the participants had neutrophil and platelet engraftment by 42 days after infusion.
๐Ÿ”— https://www.nejm.org/doi/full/10.1056/NEJMoa2501277

๐‚๐š๐ฅ๐ฅ๐ข๐ง๐  ๐€๐ฅ๐ฅ ๐ƒ๐จ๐  ๐Ÿถ ๐Ž๐ฐ๐ง๐ž๐ซ๐ฌ!This week, The Ohio State University College of Veterinary Medicine and Lamassu Pets, the veter...
03/26/2026

๐‚๐š๐ฅ๐ฅ๐ข๐ง๐  ๐€๐ฅ๐ฅ ๐ƒ๐จ๐  ๐Ÿถ ๐Ž๐ฐ๐ง๐ž๐ซ๐ฌ!

This week, The Ohio State University College of Veterinary Medicine and Lamassu Pets, the veterinary division of Lamassu Biotech, started accepting canine patients for a new clinical trial testing a canine-specific application of RABI-767, a novel therapeutic targeting acute pancreatitis, a life-threatening condition that currently has no effective treatments in either human or veterinary medicine.
The trial, which is supported by the National Institutes of Health (NIH), involves a single injection of the drug delivered directly around the pancreas. The therapy aims to mitigate symptoms, reduce complications and protect against organ failure.
This clinical trial has the potential to make a significant impact on the field of veterinary medicine. The data collected from the canine trials will also help accelerate the development of a companion treatment for humans.

๐Ÿ“ฐ Full Announcement: https://www.lamassubiotech.com/2026/03/25/ohio-state-launches-clinical-trial-for-promising-new-treatment-for-acute-pancreatitis-in-dogs/
๐Ÿ’‰ Trial Details: https://vmc.vet.osu.edu/clinical-trials-office/current-trials

03/26/2026

๐Ÿ›ก ๐ƒ๐ซ๐ฎ๐  ๐๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ ๐š๐ฅ๐ฐ๐š๐ฒ๐ฌ ๐›๐ž๐ ๐ข๐ง๐ฌ ๐ฐ๐ข๐ญ๐ก ๐จ๐ง๐ž ๐ช๐ฎ๐ž๐ฌ๐ญ๐ข๐จ๐ง: ๐ˆ๐ฌ ๐ข๐ญ ๐ฌ๐š๐Ÿ๐ž?

In oncology, ๐ญ๐จ๐ฑ๐ข๐œ๐ข๐ญ๐ฒ ๐ซ๐ž๐ฆ๐š๐ข๐ง๐ฌ ๐ญ๐ก๐ž #๐Ÿ ๐ซ๐ž๐š๐ฌ๐จ๐ง ๐Ÿ๐จ๐ซ ๐ž๐š๐ซ๐ฅ๐ฒ-๐ฌ๐ญ๐š๐ ๐ž ๐Ÿ๐š๐ข๐ฅ๐ฎ๐ซ๐ž๐ฌ. Analysis from the Tufts Center shows that in both ๐๐ก๐š๐ฌ๐ž ๐ˆ ๐š๐ง๐ ๐ˆ๐ˆ๐ˆ, about ๐จ๐ง๐ž-๐ญ๐ก๐ข๐ซ๐ ๐จ๐Ÿ ๐๐ซ๐ฎ๐  ๐Ÿ๐š๐ข๐ฅ๐ฎ๐ซ๐ž๐ฌ ๐š๐ซ๐ž ๐๐ฎ๐ž ๐ญ๐จ ๐ฌ๐š๐Ÿ๐ž๐ญ๐ฒ ๐œ๐จ๐ง๐œ๐ž๐ซ๐ง๐ฌ.

That makes safety non-negotiableโ€”not just a box to tick, but the foundation of sustainable drug development. Itโ€™s why at Lamassu Biotech, our investigational program ๐’๐€๐Ÿ“๐Ÿ‘ ๐ข๐ฌ ๐›๐ฎ๐ข๐ฅ๐ญ ๐ฐ๐ข๐ญ๐ก ๐š โ€œ๐ฌ๐š๐Ÿ๐ž๐ญ๐ฒ-๐Ÿ๐ข๐ซ๐ฌ๐ญโ€ ๐ฉ๐ก๐ข๐ฅ๐จ๐ฌ๐จ๐ฉ๐ก๐ฒ ๐Ÿ๐ซ๐จ๐ฆ ๐๐š๐ฒ ๐จ๐ง๐ž.

We embed rigorous early screening, risk assessment, and safety analytics into every stageโ€”from molecular design to preclinical validationโ€”to minimize risk and maximize patient confidence.

๐€๐ญ ๐‹๐š๐ฆ๐š๐ฌ๐ฌ๐ฎ ๐๐ข๐จ๐ญ๐ž๐œ๐ก, ๐ฌ๐š๐Ÿ๐ž๐ญ๐ฒ ๐ข๐ฌ๐งโ€™๐ญ ๐š๐ง ๐š๐Ÿ๐ญ๐ž๐ซ๐ญ๐ก๐จ๐ฎ๐ ๐ก๐ญโ€”๐ข๐ญโ€™๐ฌ ๐ญ๐ก๐ž ๐ฌ๐ญ๐š๐ซ๐ญ๐ข๐ง๐  ๐ฉ๐จ๐ข๐ง๐ญ.

โš ๏ธ Disclaimer: SA53 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.
๐Ÿ“š Source: Hay M et al., Nat Biotechnol. 2014;

๐Ÿ” ๐๐š๐ง๐œ๐ซ๐ž๐š๐ญ๐ข๐ญ๐ข๐ฌ: ๐ฌ๐ž๐ฉ๐š๐ซ๐š๐ญ๐ข๐ง๐  ๐ฆ๐ฒ๐ญ๐ก ๐Ÿ๐ซ๐จ๐ฆ ๐ซ๐ž๐š๐ฅ๐ข๐ญ๐ฒ.Myth 1: โ€œPancreatitis = alcohol only.โ€๐Ÿ‘‰ Reality: Gallstones are actually th...
03/24/2026

๐Ÿ” ๐๐š๐ง๐œ๐ซ๐ž๐š๐ญ๐ข๐ญ๐ข๐ฌ: ๐ฌ๐ž๐ฉ๐š๐ซ๐š๐ญ๐ข๐ง๐  ๐ฆ๐ฒ๐ญ๐ก ๐Ÿ๐ซ๐จ๐ฆ ๐ซ๐ž๐š๐ฅ๐ข๐ญ๐ฒ.

Myth 1: โ€œPancreatitis = alcohol only.โ€
๐Ÿ‘‰ Reality: Gallstones are actually the leading cause, responsible for ~40โ€“70% of cases.

Myth 2: โ€œItโ€™s always mild.โ€
๐Ÿ‘‰ Reality: Severe pancreatitis can be life-threatening, with complications that require intensive care.

At Lamassu Biotech, ๐จ๐ฎ๐ซ ๐ข๐ง๐ฏ๐ž๐ฌ๐ญ๐ข๐ ๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐ฉ๐ซ๐จ๐ ๐ซ๐š๐ฆ ๐‘๐€๐๐ˆ-๐Ÿ•๐Ÿ”๐Ÿ• ๐ข๐ฌ ๐Ÿ๐จ๐œ๐ฎ๐ฌ๐ž๐ ๐จ๐ง ๐š๐๐๐ซ๐ž๐ฌ๐ฌ๐ข๐ง๐  ๐ญ๐ก๐ž ๐ฎ๐ง๐๐ž๐ซ๐ฅ๐ฒ๐ข๐ง๐  ๐ฆ๐ž๐œ๐ก๐š๐ง๐ข๐ฌ๐ฆ๐ฌ ๐จ๐Ÿ ๐š๐œ๐ฎ๐ญ๐ž ๐ฉ๐š๐ง๐œ๐ซ๐ž๐š๐ญ๐ข๐ญ๐ข๐ฌ โ€” because the myths donโ€™t capture the true burden of this disease.

โš ๏ธ Disclaimer: RABI-767 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.
๐Ÿ“š Source: Yadav D, Lowenfels AB. N Engl J Med. 2013.

Address

Cleveland, OH

Website

Alerts

Be the first to know and let us send you an email when Lamassu BioTech posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category